Literature DB >> 19965820

Long-term response to fractionated radiotherapy of presumed optic nerve sheath meningioma.

Robert L Lesser1, Jonathan P S Knisely, Silas L Wang, James B Yu, Mark J Kupersmith.   

Abstract

BACKGROUND/AIMS To review the long-term results of treatment of optic nerve sheath meningiomas (ONSMs) with conformal radiotherapy. METHODS Eleven patients with presumed ONSM were treated with fractionated conformal radiotherapy using 45-54 Gy in 25-30 fractions and followed for more than 5 years. Affected eye visual acuity in logMAR notation, colour vision, threshold perimetry, mean deviation (dB) and imaging were studied before and after treatment. ANALYSIS Included adverse effects of treatment and the frequency of affected eye maintained or improved vision. RESULTS There were nine women and two men with a mean age of 45.3. Vision or field loss was the most common presentation. All had abnormal MR imaging. The follow-up period after radiotherapy was 61-156 months (mean 89.6). Visual acuity was unchanged or improved in 10 patients (91%). The average difference between pretreatment and final logMAR visual acuity was 0.08, while the average difference in visual-field mean deviation was -4.63 dB. The radiographic appearance of the tumours was stable in size in nine patients and decreased in two. No major side effects from radiation were seen. CONCLUSIONS Vision, MRI and complication outcomes are favourable for using fractionated conformal radiotherapy for ONSM.

Entities:  

Mesh:

Year:  2009        PMID: 19965820     DOI: 10.1136/bjo.2009.167346

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  10 in total

1.  [Therapy of posterior orbital tumors].

Authors:  W Maier; G J Ridder; J Kaminsky; A L Grosu
Journal:  Ophthalmologe       Date:  2011-06       Impact factor: 1.059

2.  Primary and Secondary Optic Nerve Sheath Meningioma.

Authors:  Elena Solli; Roger E Turbin
Journal:  J Neurol Surg B Skull Base       Date:  2021-02-18

3.  Efficacy of intensity-modulated radiation therapy for optic nerve sheath meningioma.

Authors:  Hiroyuki Sasano; Keigo Shikishima; Manabu Aoki; Tsutomu Sakai; Yuki Tsutsumi; Tadashi Nakano
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-08-03       Impact factor: 3.117

4.  Analyses on the misdiagnoses of 25 patients with unilateral optic nerve sheath meningioma.

Authors:  Jun-Feng Mao; Xiao-Bo Xia; Xiang-Bo Tang; Xue-Yong Zhang; Dan Wen
Journal:  Int J Ophthalmol       Date:  2016-09-18       Impact factor: 1.779

5.  Prolonged vision return after radiosurgery for an optic nerve-sheath meningioma.

Authors:  Ali Kooshkabadi; Ismayilov Elchin; Hideyuki Kano; L Dade Lunsford
Journal:  J Radiosurg SBRT       Date:  2012

6.  Fusiform appearance of optic nerve sheath meningioma: Correlating clinical and imaging findings.

Authors:  Konstantinos T Tsaousis; Dimitrios Balatsoukas
Journal:  Oman J Ophthalmol       Date:  2012-01

7.  Surgical Resection of an Optic Nerve Sheath Meningioma: Relevance of Endoscopic Endonasal Approaches to the Optic Canal.

Authors:  Patrick J Hunt; Franco DeMonte; Rosa A Tang; Shirley Y Su; Shaan M Raza
Journal:  J Neurol Surg Rep       Date:  2017-04

Review 8.  Optic nerve sheath meningiomas: prevalence, impact, and management strategies.

Authors:  Richard T Parker; Christopher A Ovens; Clare L Fraser; Chameen Samarawickrama
Journal:  Eye Brain       Date:  2018-10-24

9.  Prognostic Factors for Functional Outcome of Patients with Optic Nerve Sheath Meningiomas Treated with Stereotactic Radiotherapy-Evaluation of Own and Meta-Analysis of Published Data.

Authors:  Bogdan Pintea; Azize Boström; Sotiris Katsigiannis; Konstantinos Gousias; Rares Pintea; Brigitta Baumert; Jan Boström
Journal:  Cancers (Basel)       Date:  2021-01-29       Impact factor: 6.639

10.  Optic Nerve Sheath Meningioma: Preliminary Analysis of the Role of Radiation Therapy.

Authors:  Jun Jin; Jin Deok Joo; Jung Ho Han; Hee Kyung Yang; Jeong Min Hwang; Yi Jun Kim; In Ah Kim; Chae Yong Kim
Journal:  Brain Tumor Res Treat       Date:  2018-04-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.